PERSONAL INFORMATION
Name: Weiying Zhou
Gender: Famale
Title: Full professor
Position: Director of Phamacology,College of Pharmacy,
Chongqing Medical University, Chongqing, PR.China
CONTACT INFORMATION
Email: wyzhou0118@cqmu.edu.cn
Address: No. 1 Yixueyuan Road, Yuzhong district, Chongqing 400016, PR.China.
Phone: +86-13110216025
EDUCATION EXPERIENCE
2004.07—2007.06 Ph.D, Major: Clinical Laboratory Diagnostics
Department of Clinical Microbiology and Immunology, Third Military Medical University), Chongqing,China
2001.09—2004.06 MS, Major: Veterinary medicine
Department of Animal Science and Technology, Southwest University（formerly Southwest Agriculture University）, Chongqing, China
1997.09—2001.06 BS, Major: Veterinary medicine
Department of Animal Science and Technology,Southwest University（formerly Southwest Agriculture University）, Chongqing, China
WORKING EXPERIENCE
2017.02—present Full professor, Director of Phamacology, College of Pharmacy, Chongqing Medical University, P.R.China
2015.12—2017.01 Full professor, Department of Pharmacology, Third Military Medical University, P.R.China
2011.04—2014.04 Visiting investigator, City of Hope Beckman Research Institute and Medical Center, Duarte, CA, USA
2009.09—2015.11 Associate professor, Department of Pharmacology, Third Military Medical University, P.R.China
2007.09—2009.8 Lecturer, Department of Pharmacology, Third Military Medical University, P.R.China
RESEARCH INTERESTS
Pharmacology of anti-cancer drugs; pharmacology of anti-metabolic disorders.
Focus on the basic biological aspects of breast cancer and prostate cancer, such as the mechanisms of invasion and metastasis and chemotherapy resistance; explore new strategies to antagonize invasion and metastasis and reverse drug resistance; identify new targets for drug action, and conduct drug design, screening and pharmacology related research.
Focus on the new mechanisms of diabetes mellitus, and explore new targets of anti-diabetic drugs and new strategies for drug development.
FUNDING INFORMATION AS PRINCIPLE INVESTIGATOR
1. National Natural Science Foundation(82373901), The Mechanism of SGK3/BECN1 Signaling Promoting Autophagy-Mediating Tamoxifen Resistance in breast cancer, 2024.01.01-2027.12.30;PI
2. Chongqing Science and Technology Commission（2022NSCQ-LZX0068）, The role and mechanism of exosomal AREG/SGK3 signal mediating the crosstalk between tumor cells and microenvironment to promote the development of breast cancer. 2022-11-01 -2025-12-31;PI
3. National Natural Science Foundation(82173869)，Study on the anti-type 2 diabetes effect and mechanism of Celastrol targeting ChREBP/TXNIP axis, 2022.01.01-2025.12.30; PI
4. National Natural Science Foundation(81874100), Endoplasmic reticulum stress inhibits androgen receptor (AR) transcription: experimental study on the treatment of castration-resistant prostate cancer, 2019.01.01-2022.12.30; PI
5. National Natural Science Foundation(81472483), Exosomal miR-105 secreted by breast cancer cells promotes cancer progression by educating micro-environmental cells through c-Myc, 2015.01-2018.12 ; PI
6. Basic Research and Frontier Exploration Project of Chongqing Science and Technology Commission (cstc2021ycjh-bgzxm0133) , 2021.06.01-2023.12.30 ; PI
7. Innovation research group in Colleges and Universities Program of Chongqing Municipal Education Commission (No. CXQT20012) , 2020.07.01-2023.06.30 ;PI
8. Postgraduate Tutor Team Development Program of Chongqing Municipal Education Commission （No. dstd201807）2018.12.30-2021.12.30 ;PI
9. Chongqing Science and Technology Commission (cstc2017shmsA0876.Study on Pharmacodynamics of QiHu Preparation for Diabetes , 2017.09-2020.08; PI
10. National Nature and Science Foundation of China (NSFC81000715), The role of DC-SIGN in immune escape of staphylococcus aureus, 2011.01.01-2013.12.31; PI
11. Chongqing Science and Technology Commission (CSTC,2008BB5114), Design and experimental study on vaccine against staphylococcus aureus, 2008.09.01-2011 .08.31. PI.
PUBLICATIONS
1. Duanfang Zhou, Xiaoli Li , Xiaoqiu Xiao , Gang Wang , Bo Chen , Yi Song , Xu Liu , Qichen He, Huan Zhang, Qiuya Wu, Limei Zhang, Lihong Wu, Zhengze Shen, Moustapha Hassan , Ying Zhao , Weiying Zhou. Celastrol targets the ChREBP-TXNIP axis to ameliorates type 2 diabetes mellitus. Phytomedicine,110, February 2023, 154634
2. Bo Chen, Xiaoli Li , Lihong Wu, Duanfang Zhou, Yi Song, Limei Zhang, Qiuya Wu, Qichen He, Gang Wang, Xu Liu, Hui Hu, Weiying Zhou. Quercetin Suppresses Human Glioblastoma Migration and Invasion via GSK3β/β-catenin/ZEB1 Signaling Pathway. Frontiers in Pharmacology. 2022,Nov 01;13
3. Qiuya Wu, Duanfang Zhou , Zhengze Shen , Bo Chen, Gang Wang , Lihong Wu , Limei Zhang, Xiaoli Li, Lie Yuan, Yuanli Wu, Na Qu, Weiying Zhou. VPS34-IN1 induces apoptosis of ER+ breast cancer cells via activating PERK/ATF4/CHOP pathway. Biochemical Pharmacology 214 (2023) 115634. https://doi.org/10.1016/j.bcp.2023.115634
4. Limei Zhang, Lihong Wu, Duanfang Zhou, Gang Wang, Bo Chen, Zhengze Shen, Xiaoli Li, Qiuya Wu, Na Qu, Yuanli Wu, Lie Yuan, Zongjie Gan, Weiying Zhou. N76-1, a novel CDK7 inhibitor, exhibits potent anti-cancer effects in triple negative breast cancer. European Journal of Pharmacology 955 (2023) 175892. https://doi.org/10.1016/j.ejphar.2023.175892
5. Hongmei Wang1,2,3,4 · Xuefeng Shan5 · Min Zhang6 · Kun Qian7 · Zhengze Shen8 · Weiying Zhou. Nomograms for predicting overall survival in colorectal cancer patients with metastasis to the liver, lung, bone, and brain. Cancer Causes & Control.July,2023. https://doi.org/10.1007/s10552-023-01744-5
6. Hongmei Wang, Xuefeng Shan, Yang Peng, Weiying Zhou. Circular RNAs in the chemoresistance of triple‐negative breast cancer: A systematic review. Drug Dev Res.( REVIEW) 2023;1–10, DOI: 10.1002/ddr.22069
7. Qichen He, Bo Chen, Gang Wang, Duanfang Zhou, Hongfang Zeng,Xiaoli Li, Yi Song, Xiaoping Yu, Wenxin Liang, Huilin Chen1, Xu Liu,Qiuya Wu, Lihong Wu, Limei Zhang, Huizhen Li, Xiangnan Hu and Weiying Zhou. Co-Crystal of Rosiglitazone With Berberine Ameliorates Hyperglycemia and Insulin Resistance Through the PI3K/AKT/TXNIP Pathway In Vivo and In Vitro. Frontiers in Pharmacology.2022:10（IF5.988, JCRQ1，通讯作者）DOI: 10.3389/fphar.2022.842879
8. Duanfang Zhou, Xiaoping Yu,Yi Song Hongfang Zeng, Huan Zhang, Bo Chen Yalan Wang4, Hongyao Li, Xu Liu, Qichen He, Xiaoli Li and Weiying Zhou.Screening of and mechanism underlying the action of serum- and glucocorticoid-regulated kinase 3-targeted drugs against estrogen receptor-positive breast cancer . European Journal of Pharmacology. 2022.5, 927:174982 DOI:10.1016/j.ejphar.2022.174982
9. Xiaoli Li, Duanfang Zhou, Yongqing Cai, Xiaoping Yu, Xiangru Zheng , Bo Chen , Wenjun Li , Hongfang Zeng, Moustapha Hassan，Ying Zhao，Weiying Zhou. Ndoplasmic reticulum stress inhibits AR expression via PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple negative breast cancer and prostate cancer. npj Breast Cancer (2022) 8:2; https://doi.org/10.1038/s41523-021-00370-1.
10. Xiaoli Li, Xiaoping Yu, Duanfang Zhou, Bo Chen, Wenjun Li , Xiangru Zheng , Hongfang Zeng, Liangyuan Long, Weiying Zhou. CCT020312 inhibits triple-negative breast cancer through PERK pathway to induce apoptosis and G1 phase arrest. Frontiers in Pharmacology.2020:11,737..DOI:10.3389/fphar.2020.00737
11. Weiying Zhou, Miranda Y. Fong, Liang Liu, Yongfen Min, Yang Yu, Amy Chow, Sean Timothy Francis O'Connor1, Andrew R. Chin, George Somlo, Melanie R.Palomares, Eric G. Marcusson, Peiguo Chu, Xiwei Wu, Arthur Xuejun Li, ZhuoLi, Hanlin Gao, Xiubao Ren, Mark P. Boldin, Pengnian Charles Lin, and Shizhen Emily Wang. Cancer-Secreted miR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis, Cancer Cell, 2014，25（4）：501–515.DOI:http://dx.doi.org/10.1016/j.ccr.2014.03.007.
12. Hongfang Zeng, Xiaoli Li, Duanfang Zhou, Ning Wang, Xiaoping Yu, Liangyuan Long, Hao Cheng, Shuyu Zhou, Weiying Zhou. The Qihu preparation ameliorates diabetes ty activating the AMPK signaling pathway in db/db mice. Diabetes, Metabolic Syndrome and Obesity Targets and Therapy, 2021.07:14:3229-3241, https//doi.org/10.2147/DMSO.S312137.
13. Qichen He, Bo Chen, Gang Wang, Duanfang Zhou, Hongfang Zeng,Xiaoli Li, Yi Song, Xiaoping Yu, Wenxin Liang, Huilin Chen1, XuLiu, Qiuya Wu, Lihong Wu, Limei Zhang, Huizhen Li, Xiangnan Hu and Weiying Zhou. Co-Crystal of Rosiglitazone With Berberine Ameliorates Hyperglycemia and Insulin Resistance Through the PI3K/AKT/TXNIP Pathway In Vivo and In Vitro. Frontiers in Pharmacology.2022:10.DOI: 10.3389/fphar.2022.842879
14. Liangyuan Long，Xiangnan Hu，Xiaoli Li，Duanfang Zhou，YunShi，Lingen Wang，HongfangZeng，Xiaoping Yu，Weiying Zhou. The anti-breast cancer effect and mechanism of glimepiride-metformin adduct.OncoTargets and Therapy，2020:13，3777–3788.DOI.org/10.2147/OTT.S240252
15. Xiaoli Li,Guangbei Zhu, Xintong Yao, Ning Wang, Ronghui Hu, Qingxin Kong, Duanfang Zhou, Liangyuan Long, JialiCai, Weiying Zhou. Celastrol induces ubiquitin-dependent degradation of mTOR in breast cancer cells. OncoTargets and Therapy. OncoTargets and Therapy 2018:11 8977–8985.DOI:10.2147/OTT.S187315
16. Miranda Y. Fong, Weiying Zhou, Liang Liu, Aileen Y. Alontaga,Manasa Chandra, Jonathan Ashby,Amy Chow, Sean Timothy Francis O'Connor, Shasha Li, Andrew R. Chin, George Somlo,MelaniePalomares, Zhuo Li, Jacob R. Tremblay, Akihiro Tsuyada, GuoqiangSun,Michael A. Reid,XiweiWu, PiotrSwiderski, XiubaoRen, Yanhong Shi9,Mei Kong,WenwanZhong, Yuan Chen,andShizhen Emily Wang. Breast cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nature Cell Biology, 2015,17（2）：183-194 , doi:10.1038/ncb3094
17. Amy Chow, Weiying Zhou, Liang Liu, Miranda Y. Fong, Jackson Champer, Desiree Van Haut, Andrew R. Chin, XiubaoRen, Bogdan Gabriel Gugiu, ZhipengMeng, Wendong Huang, Vu Ngo, MarcinKortylewski, Shizhen Emily Wang. Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB. SCIENTIFIC REPORTS, | 4 : 5750 | DOI: 10.1038/srep05750:1-11..
18. Wei Yan, Xiwei Wu, Weiying Zhou, Miranda Y. Fong, Minghui Cao, Juan Liu, Xiaojing Liu,Chih-Hong Chen, OluwoleFadare, Donald P. Pizzo, Jiawen Wu, Liang Liu, Xuxiang Liu,Andrew R. Chin, XiubaoRen, Yuan Chen, Jason W. Locasale and Shizhen Emily Wang. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nature Cell Biology, 2018,20 (5):597–609.
19. Liang Liu,Weiying Zhou,Chun-Ting Cheng,Xiubao Ren,George Somlo,MirandaY.Fong, Andrew R. Chin,Hui Li,Yang Yu,Yang Xu,Sean Timothy Francis O'Connor, Timothy R. O'Connor, David K. Ann,Jeremy M. Stark, and Shizhen Emily Wang. TGFβ Induces ‘BRCAness’ and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA Repair Genes. Mol Cancer Res，2014 Nov;12(11):1597-609
20. Ping Cheng, Tao Liu, Wei-Ying Zhou, Yuan Zhuang, Liu-sheng Peng, Jin-yu Zhang, Zhi-Nan Yin,Xu-hu Mao, Gang Guo, Yun Shi, and Quan-ming Zou.Role of gamma-delta T cells in host response against Staphylococcus aureus-induced pneumonia. BMC Immunology 2012, 13:38，1-10
21. Zhou WY, Shi Y, Wu C, Zhang WJ, Mao XH, Guo G, Li HX, Zou QM. Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine. 2009 ; 27(36):5013-5019.
22. Wu C, Shi Y，Guo H, Zhou WY, Liu KY, Zou QM. Protection against Helicobacter pylori infection in Mongolian gerbil by intragastric or intramuscular administration with H. pylori multicomponent vaccine. Helicobacter. 2008;12,191-199
23. Shi Y, Wu C, Zhou WY, Mao XH, Guo G, Zou QM. Identification of H-2(d) restricted Th epitopes in Urease B subunit of Helicobacter pylori. Vaccine. 2007; 25(14): 2583-2590.
REFERENCE WEBSITE
https://english.cqmu.edu.cn/Faculty___Research/Academic_Faculty.htm
https://gs.cqmu.edu.cn/Gmis/dsfc/dsfcgrxx/2DE10AE922220DCA524E7D2C66C5A402
